Fresenius Medical Care AG Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NYSE
Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care AG updated their Schedule 13D filing for Humacyte, Inc., reporting a decreased beneficial ownership percentage due to share dilution and announcing key management changes within Fresenius.
NYSE
Fresenius Medical Care AG's beneficial ownership in Humacyte, Inc. decreased to 9.9% due to an increase in Humacyte's outstanding shares following a recent offering.
NYSE
SCHEDULE 13D/A: Fresenius KGaA Reduces Stake in Fresenius Medical Care AG to 28.6% Following Share Placement
Fresenius SE & Co. KGaA has reduced its beneficial ownership in Fresenius Medical Care AG to approximately 28.6% after selling 10.6 million shares in an accelerated book building process.
NYSE
SCHEDULE 13D/A: Fresenius SE & Co. KGaA Executes Strategic Portfolio Optimization with Fresenius Medical Care AG Share Placement and Exchangeable Bond Offering
Fresenius SE & Co. KGaA is strategically reducing its stake in Fresenius Medical Care AG through a share placement and the issuance of exchangeable bonds, aiming for portfolio optimization and enhanced financial stability.